|Articles|March 1, 1998

Clinical and Economic Aspects of Obesity Management: A Managed Care Perspective
Volume 4
Issue 3 Suppl

Clinical Efficacy and Safety of Antiobesity Agents

Author(s)Robert F. Kushner, MD

Download PDF: Clinical Efficacy and Safety of Antiobesity Agents

Articles in this issue

over 28 years ago

Article

Participating Faculty

over 28 years ago

Article

Obesity: Why Is It Worth Another Look?

over 28 years ago

Article

Obesity Management: A Comprehensive Plan

over 28 years ago

Article

Weight Management Partnership: MCOs and Employers

over 28 years ago

Article

The Clinical and Economic Aspects of Obesity Management: A Managed Care Perspective (Faculty Question-and-Answer Session)

over 28 years ago

Article

Selected Abstracts

over 28 years ago

Article

CME/CPE Quiz

over 28 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Clinical Efficacy and Safety of Antiobesity Agents

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Childhood Influenza Vaccine Rates Decreased From 2017 to 2023